Medicine of "Covid-19" - 10 things to know

The whole world suffering from this pandemic situation called the corona. The United States, Italy, China, India, Pakistan, Japan. the situation is out of control as if now. there is no medicine till today in the world to prevent this disease.

now the time is changed and I am very happy to share with you that, one of the leading pharmaceutical companies named Glenmark Pharmaceuticals Ltd. has launched the medicine to treat the patients of the corona.

Glenmark is known as a research-based - leading - integrated pharma company. it is available globally.

the product they have launched to treat corona patient, it contains favipiravir and the brand name is Fabiflu. as they have successfully tried in 

Favipiravir is approved in japan at the year of 2014 for the treatment of novel influenza virus infections. it inhibiting RNA polymerase activity.

Glenmark Pharma has received first approval to manufacture and market favipiravir in India by drug regulator. to treat only mild to moderate COVID-19 patients in India as considering the emergency situation.

How It Works & Benefits:

• Fabiflu contains favipiravir 200mg, available in tablet form.
• Favipiravir shows 88% improvements in COVID-19.with a quick reduction in viral by 4-5 days.
• the clinical improvement shows in the age group of 20 to 80 years. including the patients of having a native disease like diabetes, high blood pressure, low blood pressure, and heart attack as well as asthma.
• it is an antiviral drug. this drug has a broad spectrum of ribonucleic acid (RNA) virus coverage with clinical outcomes.
• it also provides radiological and symptomatic improvement.
• this drug available in tablet form, oral treatment.

Dosage:

		Day 1	Day 2 to max 14 days
Total Daily dose		1800mg bid	800mg bid
Morning		200mg X 9 tabs	200mg X 4 tabs Each Day
Evening		200mg X 9 tabs	200mg X 4 tabs Each Day

Caution:

• Contraindicated in patients with severe renal, hepatic impairment, pregnant and lactating women.
• should be used with caution in patients with a history of abnormalities in the metabolism of uric acid or having gout.
• contraindicated in patients with a history of hypersensitivity to favipiravir

First DCGI (Drugs Controller General of India) approval to Glenmark for the treatment of corona.

it has regulatory approval in key countries like in Russia it approved for COVID-19 as well as in India, too.

in Japan  it approved for new or emerging pandemic influenza viral

in France it approved for resistant influenza

Being further studied across the globe in the USA (United States of America), CHINA, ITALY as experimental use against COVID-19.

even more than 23 clinical studies with Favipiravir for corona currently undergoing across the globe.